Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Annals of Oncology

• Publication date

  2012-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdr487PMID 22039091
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EVALUATION OF PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL WHEN EVALUATING THE EFFECT OF CHEMOTHERAPY AND RADIOTHERAPY IN LOCALLY ADVANCED LUNG CANCER USING DATA FROM FOUR INDIVIDUAL PATIENT DATA META-ANALYSES

  2011cited by this paper
• Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

  2010cited by this paper
• Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

  2010cited by this paper
• Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials.

  2010cited by this paper
• American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.

  2009cited by this paper
• Time to Progression as a Surrogate Marker for Overall Survival in Patients with Advanced Non-small Cell Lung Cancer

  2009cited by this paper
• Detecting an overall survival benefit that is derived from progression-free survival.

  2009cited by this paper
• Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

  2009cited by this paper
• Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: Evidence from a pooled analysis of 2,838 patients randomized in 7 trials

  2008cited by this paper
• Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

  2008cited by this paper
• Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure.

  2007cited by this paper
• Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancer.

  2007cited by this paper
• Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis.

  2006cited by this paper
• Changes in the natural history of nonsmall cell lung cancer (NSCLC)—Comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990

  2006cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.

  2004cited by this paper
• Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

  2004cited by this paper
• Lung cancer--time to move on from chemotherapy.

  2002cited by this paper
• Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.

  2001cited by this paper
• Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.

  2000cited by this paper
• Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

  2000cited by this paper
• Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

  2000cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper

• Evaluating Post-Progression Survival in the Context of Progression-Free Survival Benefits: A Revisit of the CodeBreaK200 Design.

  2026cites this paper
• Predicting response to immunotherapy in lung cancer: an early HTA of predictive tests

  2025cites this paper
• Efficacy and safety of immune checkpoint inhibitors for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis

  2025cites this paper
• RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC

  2025cites this paper
• Clinical significance of post‑progression survival after chemoradiotherapy on overall survival in limited‑disease small cell lung cancer.

  2025cites this paper
• Time‐to‐Event Endpoints in Imaging Biomarker Studies

  2024cites this paper
• EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and meta-analysis.

  2023cites this paper
• Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer.

  2023cites this paper
• QALY-type preference and willingness-to-pay among end-of-life patients with cancer treatments: a pilot study using discrete choice experiment

  2023cites this paper
• Green tea extract and hydroxyl-chloroquine combination enhances apoptosis in A549 non-small cell lung cancer cells

  2023cites this paper
• Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation

  2022cites this paper
• Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival

  2022cites this paper
• Clinical Impact of Post-progression Survival in Patients with Locally Advanced Non-small Cell Lung Cancer After Chemoradiotherapy

  2022cites this paper
• Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations

  2021cites this paper
• Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma

  2021cites this paper
• Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer

  2021cites this paper
• 中国非小细胞肺癌免疫检查点抑制剂治疗专家共识（2020年版）

  2021cites this paper
• Course of postoperative relapse in non‐small cell lung cancer is strongly associated with post‐progression survival

  2021cites this paper
• The use of bevacizumab is correlated with improved post-progression survival in advanced recurrent ovarian cancer.

  2021cites this paper
• Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy

  2021cites this paper
• Anticancer mechanism of breviscapine in non-small cell lung cancer A549 cells acts via ROS-mediated upregulation of IGFBP4

  2021cites this paper
• Post-Progression Survival Highly Influences Overall Survival in Driver Gene Mutation/Translocation Negative or Unknown Type of Non-Small Cell Lung Cancer

  2021cites this paper
• Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma

  2021cites this paper
• Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.

  2021cites this paper
• Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry.

  2020cites this paper
• Impact of subsequent chemotherapy on the survival of elderly patients with extensive stage small cell lung cancer

  2020cites this paper
• The Clinical Impact of the Post-progression Survival on the Overall Survival in Elderly Patients or Those with a Poor Performance Status and Extensive-disease Small-cell Lung Cancer

  2020cites this paper
• Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.

  2020cites this paper
• Post‐progression survival is highly linked to overall survival in patients with non‐small‐cell lung cancer harboring sensitive EGFR mutations treated with first‐line epidermal growth factor receptor‐tyrosine kinase inhibitors

  2019cites this paper
• Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001

  2019cites this paper
• Chronological Trends in Progression-free, Overall and Post-progression Survival in First-line Therapy for Advanced Non-small-cell Lung Cancer.

  2019cites this paper
• Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework

  2018cites this paper
• Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis

  2018cites this paper
• Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer

  2018cites this paper
• Title Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer : updated results of the West Japan Oncology Group

  2018cites this paper
• Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China

  2018cites this paper
• Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2018cites this paper
• Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening

  2018cites this paper
• The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer

  2018cites this paper
• Surrogate endpoints for overall survival in lung cancer trials: a review

  2017cites this paper
• Clinical significance of post‐progression survival in lung cancer

  2017cites this paper
• Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy

  2017cites this paper
• Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression

  2017cites this paper
• Breviscapine suppresses the growth of non-small cell lung cancer by enhancing microRNA-7 expression

  2017cites this paper
• Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy

  2017cites this paper
• Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents.

  2016cites this paper
• Clinical impact of post‐progression survival on overall survival in elderly patients with extensive disease small‐cell lung cancer

  2016cites this paper
• Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy

  2016cites this paper
• Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide

  2016influential citation
• Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer.

  2016cites this paper
• Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China

  2016cites this paper
• Post‐progression survival and progression‐free survival in patients with advanced hepatocellular carcinoma treated by sorafenib

  2016cites this paper
• Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.

  2016cites this paper
• Why post‐progression survival and post‐relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials

  2015cites this paper
• Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer

  2015influential citation
• Relationship between progression‐free survival and overall survival in patients with advanced non‐small cell lung cancer treated with anticancer agents after first‐line treatment failure

  2015cites this paper
• Assessing benefit in trials: Are we making progress in assessing progression in cancer clinical trials?

  2015cites this paper
• Clinical impact of postprogression survival for overall survival in elderly patients (aged 75 years or older) with advanced nonsmall cell lung cancer.

  2015cites this paper
• Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy

  2015cites this paper
• Correlation of progression-free and post-progression survival with overall survival in phase III trials of first-line chemotherapy for advanced epithelial ovarian cancer.

  2015cites this paper
• Verification of the correlation between progression-free survival and overall survival considering magnitudes of survival post- progression in the treatment of four types of cancer.

  2015influential citation
• Extending survival of stage IV non-small cell lung cancer.

  2014cites this paper
• PARAMOUNT trial: reopening a window to maintenance therapy.

  2014cites this paper
• Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer

  2014cites this paper
• Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy

  2014cites this paper
• Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer.

  2014cites this paper
• Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene.

  2014influential citation
• Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study

  2013cites this paper
• Is EGF receptor–tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?

  2013cites this paper
• Endpoints in lung cancer trials: today’s challenges for clinical statistics

  2013cites this paper
• Design of clinical studies: adaptive randomization and progression-free survival (PFS) as an endpoint in clinical studies of advanced non-small cell lung cancer (NSCLC).

  2013cites this paper
• The PARAMOUNT trial in NSCLC: is the amount of benefit clinically meaningful?

  2013cites this paper
• Early palliative intervention for patients with advanced cancer.

  2013cites this paper
• Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study.

  2013cites this paper
• Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials.

  2013cites this paper
• Sorafenib for Survival Post-progression in Advanced Hepatocellular Carcinoma Unresponsive to Hepatic Arterial Infusion Chemotherapy

  2013cites this paper
• Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib

  2013cites this paper
• PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis

  2013influential citation
• Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective

  2013cites this paper
• Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer.

  2013cites this paper
• Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer.

  2013cites this paper
• Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.

  2013cites this paper
• Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies

  2012cites this paper